Current evidence supports the implementation of NfL as early and sensitive serum or plasma biomarkers for polyneuropathy, for neuropathy progression, and for assessing the effect of treatment on neuropathy in ATTRv amyloidosis. Here, NEFL is linked to polyneuropathy.